Navigation Links
Modigene Announces Closing of $12 Million Financing by Members of The Frost Group
Date:3/27/2008

- Financing Includes Equity Investment and Line of Credit -

NES-ZIONA, Israel, March 27 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board: MODG), a biopharmaceutical company applying its patented technology to develop longer-acting versions of already-approved therapeutic proteins, today announced that it has closed a $2 million equity investment by a group of private investors and has entered into a line of credit agreement that provides for the availability of an additional $10 million financing. The equity investors consist of a group led by Dr. Phillip Frost, who is also the Chairman of the Board of Modigene, and the line of credit has been extended by The Frost Group LLC. Two other directors of Modigene, Dr. Jane Hsiao and Steven Rubin, are participants in the equity financing and are members of The Frost Group.

In the equity financing, Modigene issued a convertible series A preferred security at a price of $2.50 per preferred share and under the line of credit it received an option to borrow up to $10 million at an interest rate of 10% per annum that includes warrant coverage if utilized.

"Protein therapeutics represent an increasingly significant segment of the biopharmaceutical market, and we believe that Modigene's unique technology has great potential to deliver the longer-acting drugs sought by patients and their health providers," said Dr. Frost. "We welcome this opportunity to further support this promising company."

The convertible series A preferred security automatically converts into Modigene unregistered common stock after four years at a price that will be set depending on the company's market capitalization at that time. The price targets are structured to offer more favorable terms to the investors if the company is able to significantly increase its market capitalization by at least four times during this period - a market capitalization that would benefit all shareholders.

"This financing
'/>"/>

SOURCE Modigene Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Modigene to Present at the Roth 2007 New York Investor Conference
3. GeneNews announces 2007 year end results
4. China Pharma Holdings, Inc. Announces Earnings Call for Fiscal 2007 Financial Results
5. PAREXEL Announces Date of Third Quarter Fiscal Year 2008 Earnings Release and Conference Call
6. Bayer HealthCare Affiliate MEDRAD Successfully Completes Tender Offer for Shares of Possis Medical; Announces Subsequent Offering Period
7. Vicus Therapeutics Announces Participation at 15th International Molecular Medicine Tri-Conference
8. Environmental Power Announces Opening of New Corporate Headquarters in Tarrytown, NY
9. Boston Scientific Announces Schedule for ACC 2008
10. China Biologic Products Announces One of Its R&D Projects Has Been Listed In National Torch Plan
11. Medivation Announces Senior Management Promotions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2008)...Symbol: MS, EDMONTON, Oct. 3 /PRNewswire-FirstCal...loper in the treatment of multiple sclerosis (MS),...Monitoring Board (DSMB) for the,Company,s U.S. piv...8298),in patients with secondary progressive MS ha... the trial continue as per the protocol., This wa...
(Date:10/3/2008)...or Ap3ana, CTI,s ,personalized medicine, venture, ...erapeutics, Inc. (CTI),(Nasdaq: CTIC ) announced ...t recently President and COO of a Tyr Pharma and f...mics Institute of the Novartis Research,Foundation... Bresso, Italy,CTI Europe currently conducts the ...
(Date:10/2/2008)...2 /- Helix BioPharma,Corp. ... its private,placement announced on September 30, ...ss proceeds totaling CDN$11,424,000., Each unit c...mmon share,purchase warrant, with each whole commo...urchase, subject to adjustment, one common share a...
(Date:10/2/2008)...Provides Business Update to Investors, WILMINGTON...today at an,investor conference, DuPont Vice Presi...ny,s plans to bring its two advanced biofuels prog... technical progress toward the,commercialization o...stocks,economically into biofuels., "Biobutanol a...
Breaking Biology Technology:BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 2Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 3Former Scientific Director at Genomics Institute of Novartis Research Foundation Named President of Cell Therapeutics Europe 4Helix Biopharma Closes $11.4 Million Private Placement 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 2DuPont Meeting Significant 2008 Milestones in Progressing Advanced Biofuels 3
...ge of Wisconsin has promoted William Hendee to pr... ,T. Michael Bolger, the college,s president and C...t 14 years, Bill Hendee has provided outstanding l...e of Wisconsin: biomedical research, technology tr...te School of Biomedical Sciences," Bolger said. , ...
...no-geography of other states across the Midwest, a...at,s not a psychiatric diagnosis, but instead a re...ave one or more tech centers. , ,Minnesota has th... University of Minnesota) and the Mayo Clinic in R...University and a number of research labs, and the ...
...chnologies Inc. reported a loss of $4.4 million o...ded March 31, attributing the shortfall to the tim...agents. , ,Third Wave makes clinical molecular dia... of infectious diseases and cystic fibrosis, a gen... company earned $2.8 million on revenues of $15.3 ...
...rivilege of moderating a thought-provoking roundta...er-increasing mobile work force. Hosted by IP-tele...r academics, market analysts, communications, IT e...ny one conclusion from the two-hour session, it wa...nected work- and lifestyle is driving a massive bu...
Other Biology Technology:Having two biomedical tech centers in Wisconsin will help the state 2Having two biomedical tech centers in Wisconsin will help the state 3Most of us still struggle with mobility 2Most of us still struggle with mobility 3Most of us still struggle with mobility 4
(Date:10/3/2008)...h. The United States lacks the standards to ensur...se environmental harm, says a distinguished group ...try is so young, policymakers have an exceptional ...e the industry doesn,t harm the environment. , "... industry moves out of its research and developmen...
(Date:10/3/2008)... Aluminum toxicity, a global agricultural problem...gricultural productivity for more than half of the...ts have puzzled over how toxic levels of aluminum ... is that aluminum binds to several targets in the ... and ultimately interrupting plant growth. , Now...
(Date:10/3/2008)...CTOBER 2008 - More than 8,000 international scient...ention Center to participate in the first-ever Joi...ct. 5-9. A major part of their focus will be agric... research responses to major agricultural challeng...Brown Convention Center, Houston, TX , Contact:...
(Date:10/3/2008)...Y, October 3, 2008Novel platform technologies and ...evelopment of molecular diagnostics, reports Gene... payoff for successful molecular diagnostic produc...icts that this market currently exceeds $3.2 billi...ears, according to an article in the October 1 iss...
Breaking Biology News(10 mins):Experts agree: Environmental standards needed for biofuels 2UC Riverside biochemists devise method for bypassing aluminum toxicity effects in plants 2UC Riverside biochemists devise method for bypassing aluminum toxicity effects in plants 3Agricultural research highlighted in Houston 2Genetic Engineering & Biotechnology News reports on growing role of molecular diagnostics 2Bionovo to Present at A G Edwards 2nd Annual Emerging Growth Conference 2007 522 1Bionovo to Present at A G Edwards 2nd Annual Emerging Growth Conference 2007 522 2Genstruct CEO Dr Keith Elliston Invited to Speak at Oncology Clinical Trial Summit 517 1Genstruct CEO Dr Keith Elliston Invited to Speak at Oncology Clinical Trial Summit 517 2Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 358 1Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 358 2Manic phase of bipolar disorder benefits from breast cancer medication 1070 1Manic phase of bipolar disorder benefits from breast cancer medication 1070 2Manic phase of bipolar disorder benefits from breast cancer medication 1070 3
...nd transmit information via special contact sites ...rmining what we remember and what we forget. When ...aracteristics of these contact sites change. Scien...ecular processes which cause that change. , Resea...stitute for Developmental Biology in Tübingen (no...
...g believed that bigger is better when it comes to ...rses to dinosaurs, have evolved into larger specie... two biologists at the University of California, S...ings of the National Academy of Sciences suggests ...rtly true. , The scientists found that populatio...
...es fly the coop to hunt for a new home, usually a ... which site is right: With great efficiency they n...sions. , Their technique, says Cornell University...ing until a quorum develops. , The Seeley group,s...f American Scientist, might well be used to help i...
...ng wondered how nuclear pores ?the all-important c...d out of a cell,s nucleus ?double in number to pre...w, for the first time, scientists at the Salk Inst...-like pore structures formed from scratch, and ins...s discovery adds to the picture of how a cell divi...
Other Biology News:How nerve cells stay in shape 2How nerve cells stay in shape 3Study finds evolution doesn't always favor bigger animals 2Study finds evolution doesn't always favor bigger animals 3Honeybee decision-making ability rivals any department committee 2Honeybee decision-making ability rivals any department committee 3Researchers solve mystery of how nuclear pores duplicate before cell division 2
The iEMS Incubator/Shaker HT is designed for extended temperatures. Thus, the iEMS Incubator/Shaker HT is ideal for applications such as DNA hybridization and primer extension assays. iEMS Incubator/
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. -
The iEMS Incubator/Shaker is a high performance microplate incubator and orbital shaker. Its superior temperature control and efficient orbital shaking reduce incubation times. It can incubate up to
...i-Reverse Cap Analog (ARCA) is a modified cap anal...aced with OCH3. Because of this substitution, the ...h the remaining hydroxyl group thus forcing ARCA i...lt, unlike transcripts synthesized with convention...
Biology Products: